share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K：重大事件
美股SEC公告 ·  2024/05/03 04:24

Moomoo AI 已提取核心訊息

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the first quarter of fiscal year 2024 on May 2, 2024. The company announced a slight decrease in core revenue, with $1.06 billion for Q1 2024, a 2% drop from Q1 2023. Despite the decline, Illumina's non-GAAP operating margin improved to 20.6% for the quarter. The company also reported a GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023, and non-GAAP diluted earnings per share of $0.09 for Q1 2024, up from $0.08 in Q1 2023. Illumina is reiterating its fiscal year 2024 guidance, expecting approximately flat Core Illumina revenue compared to 2023 and a non-GAAP operating margin of about 20%. Additionally, Illumina is on track to divest GRAIL, a healthcare company focused on early cancer detection, by the end of Q2 2024, following the European Commission's approval of its divestment plan in April. The divestment plan may require Illumina to provide GRAIL with approximately $1 billion in funding if a capital markets transaction is pursued.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the first quarter of fiscal year 2024 on May 2, 2024. The company announced a slight decrease in core revenue, with $1.06 billion for Q1 2024, a 2% drop from Q1 2023. Despite the decline, Illumina's non-GAAP operating margin improved to 20.6% for the quarter. The company also reported a GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023, and non-GAAP diluted earnings per share of $0.09 for Q1 2024, up from $0.08 in Q1 2023. Illumina is reiterating its fiscal year 2024 guidance, expecting approximately flat Core Illumina revenue compared to 2023 and a non-GAAP operating margin of about 20%. Additionally, Illumina is on track to divest GRAIL, a healthcare company focused on early cancer detection, by the end of Q2 2024, following the European Commission's approval of its divestment plan in April. The divestment plan may require Illumina to provide GRAIL with approximately $1 billion in funding if a capital markets transaction is pursued.
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 於2024年5月2日公佈了2024財年第一季度的財務業績。該公司宣佈核心收入略有下降，2024年第一季度爲10.6億美元，較2023年第一季度下降2％。儘管有所下降，但Illumina本季度的非公認會計准則營業利潤率仍提高至20.6％。該公司還報告稱，2024年第一季度GAAP攤薄後每股虧損爲（0.79美元），而2023年第一季度的GAAP攤薄後每股收益爲0.02美元，2024年第一季度非公認會計准則攤薄後每股收益爲0.09美元，高於2023年第一季度的0.08美元。Illumina重申了其2024財年的指導方針，預計Co...展開全部
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 於2024年5月2日公佈了2024財年第一季度的財務業績。該公司宣佈核心收入略有下降，2024年第一季度爲10.6億美元，較2023年第一季度下降2％。儘管有所下降，但Illumina本季度的非公認會計准則營業利潤率仍提高至20.6％。該公司還報告稱，2024年第一季度GAAP攤薄後每股虧損爲（0.79美元），而2023年第一季度的GAAP攤薄後每股收益爲0.02美元，2024年第一季度非公認會計准則攤薄後每股收益爲0.09美元，高於2023年第一季度的0.08美元。Illumina重申了其2024財年的指導方針，預計Core Illumina的收入與2023年相比基本持平，非公認會計准則的營業利潤率約爲20％。此外，繼歐盟委員會於4月批准撤資計劃之後，Illumina有望在2024年第二季度末之前剝離專注於癌症早期發現的醫療保健公司GRAIL。如果進行資本市場交易，撤資計劃可能要求Illumina向GRAIL提供約10億美元的資金。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Grail
    GRAL
    -- 30.290
    GeneDx Holdings
    WGS
    -- 104.390
    ENDRA Life Sciences
    NDRA
    -- 4.3000
    Star Equity
    STRR
    -- 2.4200
    Exagen
    XGN
    -- 3.880
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日